Leerink Partnrs Weighs in on MREO Q1 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Mereo BioPharma Group in a research note issued to investors on Monday, November 18th. Leerink Partnrs analyst J. Schwartz forecasts that the company will earn $0.00 per share for the quarter. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2026 earnings at $0.00 EPS.

Several other research analysts have also commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research report on Tuesday, November 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a report on Tuesday, October 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Mereo BioPharma Group presently has a consensus rating of “Buy” and an average target price of $7.50.

Mereo BioPharma Group Stock Up 2.8 %

NASDAQ:MREO opened at $3.68 on Wednesday. Mereo BioPharma Group has a 1 year low of $3.17 and a 1 year high of $5.02. The stock has a 50-day simple moving average of $4.17 and a 200-day simple moving average of $3.95.

Insider Activity at Mereo BioPharma Group

In other news, CEO Denise Scots-Knight sold 28,611 shares of Mereo BioPharma Group stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $4.47, for a total value of $127,891.17. Following the completion of the sale, the chief executive officer now owns 868,967 shares of the company’s stock, valued at $3,884,282.49. The trade was a 3.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christine Ann Fox sold 9,128 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $4.47, for a total value of $40,802.16. Following the sale, the chief financial officer now owns 108,443 shares of the company’s stock, valued at approximately $484,740.21. The trade was a 7.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 52,931 shares of company stock valued at $236,602 over the last quarter. Insiders own 4.13% of the company’s stock.

Hedge Funds Weigh In On Mereo BioPharma Group

A number of hedge funds have recently made changes to their positions in the business. Rhumbline Advisers grew its stake in shares of Mereo BioPharma Group by 70.9% in the second quarter. Rhumbline Advisers now owns 6,958 shares of the company’s stock valued at $25,000 after buying an additional 2,887 shares in the last quarter. GAMMA Investing LLC grew its position in Mereo BioPharma Group by 58.1% in the third quarter. GAMMA Investing LLC now owns 10,693 shares of the company’s stock valued at $44,000 after acquiring an additional 3,928 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Mereo BioPharma Group during the first quarter worth $54,000. BNP Paribas Financial Markets boosted its stake in shares of Mereo BioPharma Group by 581,066.7% in the first quarter. BNP Paribas Financial Markets now owns 17,435 shares of the company’s stock valued at $58,000 after purchasing an additional 17,432 shares during the period. Finally, State Street Corp purchased a new stake in Mereo BioPharma Group during the 3rd quarter worth $195,000. Hedge funds and other institutional investors own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.